id,conversation_id,created_at,date,time,timezone,user_id,username,name,place,tweet,language,mentions,urls,photos,replies_count,retweets_count,likes_count,hashtags,cashtags,link,retweet,quote_url,video,thumbnail,near,geo,source,user_rt_id,user_rt,retweet_id,reply_to,retweet_date,translate,trans_src,trans_dest
1193929604207124482,1193929604207124482,2019-11-11 22:02:54 IST,2019-11-11,22:02:54,+0530,873399943,jacobplieth,Jacob Plieth,,"My take on a few #SITC19 presentations (yes, I'm puzzled by $NKTR ) via @Vantageanalysis  https://t.co/YncMwVO59l $NXTC $PIRS $CYAD",en,"[{'screen_name': 'vantageanalysis', 'name': 'evaluate vantage', 'id': '3033767986'}]",['http://bit.ly/32xHnYp'],[],5,11,35,['sitc19'],"['nktr', 'nxtc', 'pirs', 'cyad']",https://twitter.com/JacobPlieth/status/1193929604207124482,False,,0,,,,,,,,[],,,,
1188887432730726401,1188887432730726401,2019-10-29 00:07:07 IST,2019-10-29,00:07:07,+0530,14115408,jonnajarian,Jon Najarian,,60 Seconds at #WCC2019 $TIF ‚òëÔ∏è $ROKU $SPOT $MSFT Who's Zoomin' Who? $ZM $NKTR more @MarketRebels üíÄwith @CharlieShrem and @_CryptoIQ  https://t.co/HdQmVW7C9B,en,"[{'screen_name': 'marketrebels', 'name': 'market rebellion', 'id': '817007725666242561'}, {'screen_name': 'charlieshrem', 'name': 'charlie shrem', 'id': '22682896'}, {'screen_name': '_cryptoiq', 'name': 'crypto.iq', 'id': '924702182724775936'}]",[],[],1,1,8,['wcc2019'],"['tif', 'roku', 'spot', 'msft', 'zm', 'nktr']",https://twitter.com/jonnajarian/status/1188887432730726401,False,,1,https://pbs.twimg.com/ext_tw_video_thumb/1188887334370054144/pu/img/4vg0khB5-W6dKjW6.jpg,,,,,,,[],,,,
1181603160235872257,1181603160235872257,2019-10-08 21:42:01 IST,2019-10-08,21:42:01,+0530,14115408,jonnajarian,Jon Najarian,"{'type': 'Point', 'coordinates': [40.34584, -94.8733]}",üö®Coffee ‚òïÔ∏èMachine broken with petenajarian $DPZ üçïüî• $PBYI $NKTR also $TGT üéØ check out marketrebels karen_firestone @ The Broken Mug Coffee Shop  https://t.co/S7sc4DRDo7,en,[],['https://www.instagram.com/p/B3XQHbrjv4z/?igshid=1jf8beq8s4h10'],[],1,1,8,[],"['dpz', 'pbyi', 'nktr', 'tgt']",https://twitter.com/jonnajarian/status/1181603160235872257,False,,0,,,,,,,,[],,,,
1181600463554260992,1181600463554260992,2019-10-08 21:31:18 IST,2019-10-08,21:31:18,+0530,14115408,jonnajarian,Jon Najarian,,üö®Coffee ‚òïÔ∏èMachine broken with @petenajarian $DPZ üçïüî• $PBYI $NKTR also $TGT üéØ check out @MarketRebels  https://t.co/Rfm6Y3XzNh,en,"[{'screen_name': 'petenajarian', 'name': 'pete najarian', 'id': '14292717'}, {'screen_name': 'marketrebels', 'name': 'market rebellion', 'id': '817007725666242561'}]",[],[],7,2,38,[],"['dpz', 'pbyi', 'nktr', 'tgt']",https://twitter.com/jonnajarian/status/1181600463554260992,False,,1,https://pbs.twimg.com/ext_tw_video_thumb/1181600314341941252/pu/img/LmEpVd5S4wz9yLc8.jpg,,,,,,,[],,,,
1177334439636013056,1177334439636013056,2019-09-27 02:59:38 IST,2019-09-27,02:59:38,+0530,274233761,bradloncar,Brad Loncar,,"$NKTR got kicked out of the S&amp;P 500. When it rains, it pours.",en,[],[],[],2,6,17,[],['nktr'],https://twitter.com/bradloncar/status/1177334439636013056,False,,0,,,,,,,,[],,,,
1177321077812285440,1177321077812285440,2019-09-27 02:06:33 IST,2019-09-27,02:06:33,+0530,872519322077470721,tdanetwork,TD Ameritrade Network,,Live earnings reaction with George Tsilis: üìä $MU $CCL $NKTR  https://t.co/fs0vUFOnFy,en,[],['https://www.pscp.tv/w/cF0Y0TFsWkVwZ3pyUFBtam58MVprSnpBZ05nRWdHdq9OwSJSCIUsiAkAIRW9e3ZXt79cYvwh-02GwebnrtWF'],[],0,2,8,[],"['mu', 'ccl', 'nktr']",https://twitter.com/TDANetwork/status/1177321077812285440,False,,0,,,,,,,,[],,,,
1160964014668689408,1160964014668689408,2019-08-12 22:49:25 IST,2019-08-12,22:49:25,+0530,14115408,jonnajarian,Jon Najarian,,‚è±Ô∏è60 1/2 Seconds $PINS $ROKU $NKTR $FOSL $AAPL  https://t.co/fYIlheSQG8 üé≤  https://t.co/09KwsDfuwl,pl,[],['http://www.Investitute.com/Vegas'],[],1,2,10,[],"['pins', 'roku', 'nktr', 'fosl', 'aapl']",https://twitter.com/jonnajarian/status/1160964014668689408,False,,1,https://pbs.twimg.com/ext_tw_video_thumb/1160963885429592067/pu/img/xQFvRAT7YhJbB5iN.jpg,,,,,,,[],,,,
1160882927657455617,1160882927657455617,2019-08-12 17:27:12 IST,2019-08-12,17:27:12,+0530,44438256,matthewherper,Matthew Herper,,"Biotech faces a crisis in credibility fueled by boom-era hubris.   My look at $NVS, $AMRN, and $NKTR last week.  https://t.co/ymWpxoIA6E   This one is for STAT subscribers.",en,[],['https://www.statnews.com/2019/08/12/biotech-faces-a-crisis-in-credibility-fueled-by-boom-era-hubris/'],[],5,3,8,[],"['nvs', 'amrn', 'nktr']",https://twitter.com/matthewherper/status/1160882927657455617,False,,0,,,,,,,,[],,,,
1159855472058556416,1159855472058556416,2019-08-09 21:24:28 IST,2019-08-09,21:24:28,+0530,872519322077470721,tdanetwork,TD Ameritrade Network,,"With $NKTR trading down over 30% on the day after announcing suboptimal drugs were administered in a clinical trial, @bradloncar joined @OJRenick on #MorningTradeLive to discuss the fallout.  ‚ÄúThis is a huge black eye. It really questions (Nektar‚Äôs) ability to conduct trials.‚Äù",en,"[{'screen_name': 'bradloncar', 'name': 'brad loncar', 'id': '274233761'}, {'screen_name': 'ojrenick', 'name': 'oliver renick', 'id': '1580555131'}]",[],[],1,8,24,['morningtradelive'],['nktr'],https://twitter.com/TDANetwork/status/1159855472058556416,False,,0,,,,,,,,[],,,,
1159848755912499201,1159848755912499201,2019-08-09 20:57:47 IST,2019-08-09,20:57:47,+0530,274233761,bradloncar,Brad Loncar,,Always nice to talk biotech with @OJRenick on @TDANetwork. Thanks for the discussion. $NKTR $SRPT  https://t.co/I7L90QJhIs  https://t.co/ZfbiikRWkL,en,"[{'screen_name': 'ojrenick', 'name': 'oliver renick', 'id': '1580555131'}, {'screen_name': 'tdanetwork', 'name': 'td ameritrade network', 'id': '872519322077470721'}]",['https://tdameritradenetwork.com/video/rB4AoWxVGWCBbHbdp6YFJA'],['https://pbs.twimg.com/media/EBib1qoXoAEFbv7.jpg'],0,0,16,[],"['nktr', 'srpt']",https://twitter.com/bradloncar/status/1159848755912499201,False,,1,https://pbs.twimg.com/media/EBib1qoXoAEFbv7.jpg,,,,,,,[],,,,
1159814895669526529,1159814895669526529,2019-08-09 18:43:14 IST,2019-08-09,18:43:14,+0530,873399943,jacobplieth,Jacob Plieth,,"$NKTR FUBAR. My take on yesterday's manufacturing bombshell, via @Vantageanalysis  https://t.co/gPyiRMsL3O",en,"[{'screen_name': 'vantageanalysis', 'name': 'evaluate vantage', 'id': '3033767986'}]",['http://bit.ly/2ThFDzH'],[],3,9,20,[],['nktr'],https://twitter.com/JacobPlieth/status/1159814895669526529,False,,0,,,,,,,,[],,,,
1159780278673596416,1159778464985169920,2019-08-09 16:25:40 IST,2019-08-09,16:25:40,+0530,873399943,jacobplieth,Jacob Plieth,,@ByMadeleineA Maybe $NKTR should seek advice from Vas,en,[],[],[],2,0,6,[],['nktr'],https://twitter.com/JacobPlieth/status/1159780278673596416,False,,0,,,,,,,,"[{'screen_name': 'ByMadeleineA', 'name': 'Madeleine Armstrong', 'id': '14673628'}]",,,,
1159779076632174592,1159779076632174592,2019-08-09 16:20:54 IST,2019-08-09,16:20:54,+0530,102754598,johncendpts,John Carroll,,$NKTR in a world of hurt this morning -- Mystery solved? Nektar chief says 'softening' in patient responses to bempeg was a CMC issue ‚Äî spurring a rout  https://t.co/VSKsk4db6M,en,[],['https://endpts.com/nektar-chief-says-theyve-solved-the-mystery-behind-the-disastrous-softening-in-patient-responses-to-214-spurring-a-rout-among-investors/'],[],2,3,5,[],['nktr'],https://twitter.com/JohnCendpts/status/1159779076632174592,False,,0,,,,,,,,[],,,,
1159634844223246336,1159634844223246336,2019-08-09 06:47:46 IST,2019-08-09,06:47:46,+0530,102754598,johncendpts,John Carroll,,Nektar chief says they‚Äôve solved the mystery behind the disastrous 'softening' in patient responses to ‚Äò214 ‚Äî spurring a rout among investors $NKTR -30% $1.5B in market cap  https://t.co/VSKsk4db6M,en,[],['https://endpts.com/nektar-chief-says-theyve-solved-the-mystery-behind-the-disastrous-softening-in-patient-responses-to-214-spurring-a-rout-among-investors/'],[],3,5,8,[],['nktr'],https://twitter.com/JohnCendpts/status/1159634844223246336,False,,0,,,,,,,,[],,,,
1159579041139236864,1159579041139236864,2019-08-09 03:06:02 IST,2019-08-09,03:06:02,+0530,44438256,matthewherper,Matthew Herper,,General comment to biotech investors: beware the belief that anyone knows any thing.   $SRPT $AMRN $NKTR,en,[],[],[],7,11,68,[],"['srpt', 'amrn', 'nktr']",https://twitter.com/matthewherper/status/1159579041139236864,False,,0,,,,,,,,[],,,,
1159576694623277061,1159576694623277061,2019-08-09 02:56:42 IST,2019-08-09,02:56:42,+0530,130289750,maxnisen,Max Nisen,,"$NKTR just flinging a sea of difficult to interpret post-hoc analysis out on this call, this is so bizarre. Also the fact that they appear to have had a clinically meaningful manufacturing defect in a trial like this is mind boggling.",en,[],[],[],0,0,14,[],['nktr'],https://twitter.com/MaxNisen/status/1159576694623277061,False,,0,,,,,,,,[],,,,
1159574021975027713,1159574021975027713,2019-08-09 02:46:05 IST,2019-08-09,02:46:05,+0530,274233761,bradloncar,Brad Loncar,,"Oh my, $NKTR believes some patients in trials (from two batches) received suboptimal product and this led to softening of responses. This is crazy.",en,[],[],[],5,17,55,[],['nktr'],https://twitter.com/bradloncar/status/1159574021975027713,False,,0,,,,,,,,[],,,,
1159561637365526532,1159561637365526532,2019-08-09 01:56:52 IST,2019-08-09,01:56:52,+0530,274233761,bradloncar,Brad Loncar,,$NKTR halts their stock and basically says we'll talk about this in a little bit. This has been some day of company spin.,en,[],[],[],1,0,9,[],['nktr'],https://twitter.com/bradloncar/status/1159561637365526532,False,,0,,,,,,,,[],,,,
1159559295354232832,1159559295354232832,2019-08-09 01:47:34 IST,2019-08-09,01:47:34,+0530,274233761,bradloncar,Brad Loncar,,Sounds like $NKTR is having a manufacturing issue.,en,[],[],[],1,3,13,[],['nktr'],https://twitter.com/bradloncar/status/1159559295354232832,False,,0,,,,,,,,[],,,,
1158078395621658624,1158078395621658624,2019-08-04 23:43:00 IST,2019-08-04,23:43:00,+0530,274233761,bradloncar,Brad Loncar,,Another big week of earnings.  M: $ARWR $RVNC $XLRN T: $ALNY $EDIT $NVTA $REGN $SAGE W: $ALLO $ARQL $SRPT $TEVA T: $AKBA $NKTR $PBYI $ZIOP F: $IMV $NVO  The full schedule:  https://t.co/X86shzqfJs  https://t.co/eOjGpGBpDj,en,[],['https://www.loncarblog.com/august-5-earnings'],['https://pbs.twimg.com/media/EBHGOf1W4AI4zh5.jpg'],2,16,38,[],"['arwr', 'rvnc', 'xlrn', 'alny', 'edit', 'nvta', 'regn', 'sage', 'allo', 'arql', 'srpt', 'teva', 'akba', 'nktr', 'pbyi', 'ziop', 'imv', 'nvo']",https://twitter.com/bradloncar/status/1158078395621658624,False,,1,https://pbs.twimg.com/media/EBHGOf1W4AI4zh5.jpg,,,,,,,[],,,,
1156904098584809472,1135468115968626689,2019-08-01 17:56:45 IST,2019-08-01,17:56:45,+0530,873399943,jacobplieth,Jacob Plieth,,BTD now officially known as Blatantly Trivial Distraction $BMY $NKTR  https://t.co/J5xDDrzUv3,en,[],['https://twitter.com/BioStocks/status/1156882530261524480'],[],1,1,8,[],"['bmy', 'nktr']",https://twitter.com/JacobPlieth/status/1156904098584809472,False,https://twitter.com/BioStocks/status/1156882530261524480,0,,,,,,,,[],,,,
1136294049755873281,1136294049755873281,2019-06-05 20:59:47 IST,2019-06-05,20:59:47,+0530,873399943,jacobplieth,Jacob Plieth,,Who won and who lost #ASCO19 ? Our postmortem of a meeting low on data and high on stock movement  https://t.co/xrYVIsWQqi $MRTX $AMGN $MGNX $IOVA $INCY $ARRY $TPTX $NKTR $ADRO,en,[],['https://www.evaluate.com/vantage/articles/events/conferences/asco-2019-event-analyser-low-key-meeting-belies-some-huge-stock'],[],3,10,14,['asco19'],"['mrtx', 'amgn', 'mgnx', 'iova', 'incy', 'arry', 'tptx', 'nktr', 'adro']",https://twitter.com/JacobPlieth/status/1136294049755873281,False,,0,,,,,,,,[],,,,
1135571198983778304,1134494340393459713,2019-06-03 21:07:26 IST,2019-06-03,21:07:26,+0530,274233761,bradloncar,Brad Loncar,,"@TDANetwork @OJRenick A follow up on those ASCO stocks we discussed on Friday:  $IOVA +9.1% $NKTR +11.9% $AMGN +5.2%  Also, $MRTX is tied to one of the the key $AMGN drugs: +35.3%",en,[],[],[],3,5,9,[],"['iova', 'nktr', 'amgn', 'mrtx', 'amgn']",https://twitter.com/bradloncar/status/1135571198983778304,False,,0,,,,,,,,"[{'screen_name': 'TDANetwork', 'name': 'TD Ameritrade Network', 'id': '872519322077470721'}]",,,,
1135468115968626689,1135468115968626689,2019-06-03 14:17:49 IST,2019-06-03,14:17:49,+0530,873399943,jacobplieth,Jacob Plieth,,4 PRs have converted to CRs. Same ORR as at #SITC18 What else is actually new in this #ASCO19 dataset? $NKTR  https://t.co/GC0Ycuh4kH,en,[],['http://bit.ly/2QCGKIX'],[],5,3,9,"['sitc18', 'asco19']",['nktr'],https://twitter.com/JacobPlieth/status/1135468115968626689,False,https://twitter.com/bradloncar/status/1135349594475261957,0,,,,,,,,[],,,,
1134944908735913989,1134944908735913989,2019-06-02 03:38:47 IST,2019-06-02,03:38:47,+0530,102754598,johncendpts,John Carroll,,#ASCO19: Struggling Nektar braves a tough crowd to offer up 4 new CRs for skin cancer drug $NKTR  https://t.co/6gOzEMOPau,en,[],['https://endpts.com/asco19-struggling-nektar-braves-a-tough-crowd-to-offer-up-4-new-crs-for-skin-cancer-drug/'],[],2,4,14,['asco19'],['nktr'],https://twitter.com/JohnCendpts/status/1134944908735913989,False,,0,,,,,,,,[],,,,
1131534762055786496,1131534762055786496,2019-05-23 17:48:04 IST,2019-05-23,17:48:04,+0530,873399943,jacobplieth,Jacob Plieth,,"Can there be any reason for this other than to force the hand of a buyer, like Theravance tried? $NKTR  https://t.co/JlTtP2k9zk",en,[],['https://prn.to/2M5XiKO'],[],1,0,6,[],['nktr'],https://twitter.com/JacobPlieth/status/1131534762055786496,False,https://twitter.com/bio_clouseau/status/1131530552211910657,0,,,,,,,,[],,,,
1126233124827017221,1126233124827017221,2019-05-09 02:41:16 IST,2019-05-09,02:41:16,+0530,274233761,bradloncar,Brad Loncar,,$NKTR says they are going to present 12 month follow-up data in melanoma during #ASCO19. This is outside of their abstracts.,en,[],[],[],2,1,22,['asco19'],['nktr'],https://twitter.com/bradloncar/status/1126233124827017221,False,,0,,,,,,,,[],,,,
1125085748598730753,1125085748598730753,2019-05-05 22:42:00 IST,2019-05-05,22:42:00,+0530,274233761,bradloncar,Brad Loncar,,There are 248 earnings calls in healthcare this week. NBD  M: $ADAP $BHC $GWPH T: $AGN $ALLO $EDIT $REGN W: $ARNA $ICPT $NKTR $SRPT T: $BPMC $IONS $PBYI F: $IMV $PIRS $PTE  The full list:  https://t.co/ue44m0En8Y  https://t.co/OmoKCsfrwk,en,[],['https://www.loncarblog.com/may-6-earnings'],['https://pbs.twimg.com/media/D5yVQ-6W0AUjXCw.jpg'],2,15,36,[],"['adap', 'bhc', 'gwph', 'agn', 'allo', 'edit', 'regn', 'arna', 'icpt', 'nktr', 'srpt', 'bpmc', 'ions', 'pbyi', 'imv', 'pirs', 'pte']",https://twitter.com/bradloncar/status/1125085748598730753,False,,1,https://pbs.twimg.com/media/D5yVQ-6W0AUjXCw.jpg,,,,,,,[],,,,
1095364068381286401,1095364068381286401,2019-02-12 22:18:39 IST,2019-02-12,22:18:39,+0530,14115408,jonnajarian,Jon Najarian,,Today's 60 Second video from @investitute $ELLI $ECA $SHOP $GLID $TAPüç∫ $NKTR see you on @HalftimeReport  https://t.co/pzIGOPHhdO,en,"[{'screen_name': 'investitute', 'name': 'investitute', 'id': '1295683179412512768'}, {'screen_name': 'halftimereport', 'name': 'cnbc halftime report', 'id': '234905402'}]",[],[],2,4,16,[],"['elli', 'eca', 'shop', 'glid', 'nktr']",https://twitter.com/jonnajarian/status/1095364068381286401,False,,1,https://pbs.twimg.com/ext_tw_video_thumb/1095363581527371776/pu/img/ybQXkX1-bk2K0z7M.jpg,,,,,,,[],,,,
1067202786453000193,1067202786453000193,2018-11-27 05:15:46 IST,2018-11-27,05:15:46,+0530,102754598,johncendpts,John Carroll,,$NKTR,lt,[],[],[],2,1,4,[],['nktr'],https://twitter.com/JohnCendpts/status/1067202786453000193,False,https://twitter.com/bradloncar/status/1067199634655846400,0,,,,,,,,[],,,,
1062026699272056833,1062026699272056833,2018-11-12 22:27:51 IST,2018-11-12,22:27:51,+0530,14115408,jonnajarian,Jon Najarian,,Today 60 Second Video $AAPL $LITE $CRUS $NKTR see you on @HalftimeReport #60sec  https://t.co/wYviET6eBx,en,"[{'screen_name': 'halftimereport', 'name': 'cnbc halftime report', 'id': '234905402'}]",[],[],2,2,14,['60sec'],"['aapl', 'lite', 'crus', 'nktr']",https://twitter.com/jonnajarian/status/1062026699272056833,False,,1,https://pbs.twimg.com/ext_tw_video_thumb/1062026385647001600/pu/img/DDBDoJxxVOYMaDdj.jpg,,,,,,,[],,,,
1061621428380930048,1058029649710718977,2018-11-11 19:37:27 IST,2018-11-11,19:37:27,+0530,873399943,jacobplieth,Jacob Plieth,,"Savage comments from Evercore ISI: ""Funny how everyone but $NKTR believes they‚Äôll need randomised post-PD1 data after talking to FDA, whereas NKTR relies on some random oncologist‚Äôs comments to back AA with single-arm study""",en,[],[],[],4,1,7,[],['nktr'],https://twitter.com/JacobPlieth/status/1061621428380930048,False,,0,,,,,,,,[],,,,
1061620568703860737,1058029649710718977,2018-11-11 19:34:02 IST,2018-11-11,19:34:02,+0530,873399943,jacobplieth,Jacob Plieth,,If you're catching up on #SITC2018 news here's my take on the latest cut of $NKTR's Pivot-02 data  https://t.co/GQHyuwQdYy,en,[],['http://www.evaluate.com/vantage/articles/events/conferences/sitc-nektars-big-reveal-falls-flat'],[],3,7,16,['sitc2018'],['nktr'],https://twitter.com/JacobPlieth/status/1061620568703860737,False,,0,,,,,,,,[],,,,
1061034539164811264,1061034539164811264,2018-11-10 04:45:21 IST,2018-11-10,04:45:21,+0530,102754598,johncendpts,John Carroll,,New: The latest update on NKTR-214/Opdivo from Nektar and Bristol-Myers will keep the controversy burning over the ORR rate $NKTR  https://t.co/g7SwEEfkG3,en,[],['https://endpts.com/the-latest-update-on-nktr-214-opdivo-from-nektar-and-bristol-myers-will-keep-the-controversy-burning-over-the-orr-rate/'],[],1,10,17,[],['nktr'],https://twitter.com/JohnCendpts/status/1061034539164811264,False,,0,,,,,,,,[],,,,
1061034448874098693,1058029649710718977,2018-11-10 04:45:00 IST,2018-11-10,04:45:00,+0530,873399943,jacobplieth,Jacob Plieth,,$NKTR Pivot-02 update with Oct data cut. 53% ORR #SITC2018  https://t.co/ERqrGoV4kw,en,[],[],['https://pbs.twimg.com/media/Drk71oIXcAAmB0n.jpg'],2,10,18,['sitc2018'],['nktr'],https://twitter.com/JacobPlieth/status/1061034448874098693,False,,1,https://pbs.twimg.com/media/Drk71oIXcAAmB0n.jpg,,,,,,,[],,,,
1060597392435802112,1060597392435802112,2018-11-08 23:48:17 IST,2018-11-08,23:48:17,+0530,102754598,johncendpts,John Carroll,,"Still going strong ahead of tomorrow's reveal -- Moment of truth looms for Nektar, Bristol-Myers with a major update to NKTR-214 combo ‚Äî and the latest snapshot is not promising $NKTR  https://t.co/UeQT1t84J2",en,[],['https://endpts.com/moment-of-truth-looms-for-nektar-bristol-myers-with-a-major-update-to-nktr-214-combo-and-the-latest-snapshot-is-not-promising/'],[],1,4,6,[],['nktr'],https://twitter.com/JohnCendpts/status/1060597392435802112,False,,0,,,,,,,,[],,,,
1060279057349337089,1060279057349337089,2018-11-08 02:43:20 IST,2018-11-08,02:43:20,+0530,274233761,bradloncar,Brad Loncar,,$NKTR PR mentions that a NSCLC trial will start in a few months. Bristol was non-committal about that on their call a few weeks ago so might be a positive sign.,en,[],[],[],1,2,8,[],['nktr'],https://twitter.com/bradloncar/status/1060279057349337089,False,,0,,,,,,,,[],,,,
1059793167803924481,1058029649710718977,2018-11-06 18:32:35 IST,2018-11-06,18:32:35,+0530,873399943,jacobplieth,Jacob Plieth,,"$NKTR's big Pivot-02 reveal at #SITC2018: ORR still at an underwhelming 50%. My take, via @Vantageanalysis  https://t.co/TDyWzCGpv5",en,"[{'screen_name': 'vantageanalysis', 'name': 'evaluate vantage', 'id': '3033767986'}]",['http://www.evaluate.com/vantage/articles/events/conferences/sitc-no-honey-nektar'],[],3,14,14,['sitc2018'],['nktr'],https://twitter.com/JacobPlieth/status/1059793167803924481,False,,0,,,,,,,,[],,,,
1059366639601438720,1058029649710718977,2018-11-05 14:17:43 IST,2018-11-05,14:17:43,+0530,873399943,jacobplieth,Jacob Plieth,,Evercore: we see merit to IL-2 but believe $NKTR hasn‚Äôt optimised dose/exposure before pushing on full speed. My earlier take re #SITC2018  https://t.co/cBOe0zF6Ee,en,[],['http://www.evaluate.com/vantage/articles/events/company-events/sitc-event-nektar-hopes-pivot-away-incytes-failure'],[],2,3,6,['sitc2018'],['nktr'],https://twitter.com/JacobPlieth/status/1059366639601438720,False,,0,,,,,,,,[],,,,
1059189794633367552,1059189794633367552,2018-11-05 02:35:00 IST,2018-11-05,02:35:00,+0530,274233761,bradloncar,Brad Loncar,,There are only 237 earnings calls in healthcare this week.  M: $KURA $MYL $PTCT T: $ACAD $IONS $ONCE W: $ALNY $EDIT $NKTR T: $AZN $LOXO $SGMO F: $AXSM $RMTI $SRDX  The full list:  https://t.co/uQTDjGyr4Z  https://t.co/qLjMdbnXhu,en,[],['https://www.loncarblog.com/november-5-earnings'],['https://pbs.twimg.com/media/DrJTYxSV4AEL1KM.jpg'],2,15,31,[],"['kura', 'myl', 'ptct', 'acad', 'ions', 'once', 'alny', 'edit', 'nktr', 'azn', 'loxo', 'sgmo', 'axsm', 'rmti', 'srdx']",https://twitter.com/bradloncar/status/1059189794633367552,False,,1,https://pbs.twimg.com/media/DrJTYxSV4AEL1KM.jpg,,,,,,,[],,,,
1046701747115298816,1046701747115298816,2018-10-01 15:31:57 IST,2018-10-01,15:31:57,+0530,102754598,johncendpts,John Carroll,,Ex-Kerrisdale analyst sets out to torpedo Nektar with a blunt short attack on star drug NKTR-214: ‚ÄòIt doesn‚Äôt work‚Äô $NKTR  https://t.co/TfENCjy611,en,[],['https://endpts.com/ex-kerrisdale-analyst-sets-out-to-torpedo-nektar-with-a-blunt-short-attack-on-star-drug-nktr-214-it-doesnt-work/'],[],1,7,6,[],['nktr'],https://twitter.com/JohnCendpts/status/1046701747115298816,False,,0,,,,,,,,[],,,,
1003755378914529280,1003755378914529280,2018-06-05 03:18:25 IST,2018-06-05,03:18:25,+0530,47678782,megtirrell,Meg Tirrell,,A look at some of the biggest stock movers today out of #ASCO18: $MRK $BMY $NKTR $LOXO $BPMC $GHDX  https://t.co/Xd0RhxL7zK,en,[],['http://video.cnbc.com/gallery/?video=7000023483'],[],0,10,24,['asco18'],"['mrk', 'bmy', 'nktr', 'loxo', 'bpmc', 'ghdx']",https://twitter.com/megtirrell/status/1003755378914529280,False,,0,,,,,,,,[],,,,
1003739975345635328,1003739975345635328,2018-06-05 02:17:13 IST,2018-06-05,02:17:13,+0530,274233761,bradloncar,Brad Loncar,,#ASCO18 roundup:  $MRK üèÜ $LOXO ü•à $DCPH ü•â $IMMU üéñ $BLUE  üéñ  $NKTR ü§î $JNCE üé≠,en,[],[],[],10,25,88,['asco18'],"['mrk', 'loxo', 'dcph', 'immu', 'blue', 'nktr', 'jnce']",https://twitter.com/bradloncar/status/1003739975345635328,False,,0,,,,,,,,[],,,,
1003712374107463682,1003712374107463682,2018-06-05 00:27:32 IST,2018-06-05,00:27:32,+0530,102754598,johncendpts,John Carroll,,Not happening at $NKTR -- down 42% as panic sets in.  https://t.co/WEGqDXI0gx,en,[],['https://endpts.com/nektar-wants-everyone-to-stay-calm-as-they-carry-on-with-nktr-214-hoping-to-avoid-an-asco-stampede/'],[],1,2,10,[],['nktr'],https://twitter.com/JohnCendpts/status/1003712374107463682,False,,0,,,,,,,,[],,,,
1003707460924911617,1003707460924911617,2018-06-05 00:08:01 IST,2018-06-05,00:08:01,+0530,20562637,businessinsider,Business Insider,,We just got a lot of updates on the state of cancer treatments ‚Äî here are the winners and losers $BLUE $NKTR $LOXO $MRK $BMY  https://t.co/SwRHUugO7Q  https://t.co/tc8kS6niWL,en,[],['https://read.bi/2JgODz2'],['https://pbs.twimg.com/media/De3indQWsAI188a.jpg'],2,2,8,[],"['blue', 'nktr', 'loxo', 'mrk', 'bmy']",https://twitter.com/BusinessInsider/status/1003707460924911617,False,,1,https://pbs.twimg.com/media/De3indQWsAI188a.jpg,,,,,,,[],,,,
1003664629741047808,1003664629741047808,2018-06-04 21:17:49 IST,2018-06-04,21:17:49,+0530,14115408,jonnajarian,Jon Najarian,,60 Second Video from @investitute June 4th 2018 $IMMU @ ASCO up. $NKTR #SolarStocks $FSLR see you on @HalftimeReport #60SEC  https://t.co/WG4bDSm8dU,en,"[{'screen_name': 'investitute', 'name': 'investitute', 'id': '1295683179412512768'}, {'screen_name': 'halftimereport', 'name': 'cnbc halftime report', 'id': '234905402'}]",[],[],0,0,10,"['solarstocks', '60sec']","['immu', 'nktr', 'fslr']",https://twitter.com/jonnajarian/status/1003664629741047808,False,,1,https://pbs.twimg.com/ext_tw_video_thumb/1003664518457643008/pu/img/vC20Tji0XkReT06L.jpg,,,,,,,[],,,,
1003663490207264768,1003663490207264768,2018-06-04 21:13:17 IST,2018-06-04,21:13:17,+0530,872519322077470721,tdanetwork,TD Ameritrade Network,,$NKTR shares crash 40%. Here's why @BradLoncar says it's now the biggest battle ground in #biotech.   üìä $MRK $BMY $CNCR #ASCO2018 üì∫  https://t.co/A2r6CiMnyo  https://t.co/phqjgakZrE,en,"[{'screen_name': 'bradloncar', 'name': 'brad loncar', 'id': '274233761'}]",['http://tdameritradenetwork.com/video/ac1e00a1-63be-1de9-8163-cb788abb0002'],[],0,4,6,"['biotech', 'asco2018']","['nktr', 'mrk', 'bmy', 'cncr']",https://twitter.com/TDANetwork/status/1003663490207264768,False,,1,https://pbs.twimg.com/media/De25adDU0AAzgtm.jpg,,,,,,,[],,,,
1003626367420858368,1003626367420858368,2018-06-04 18:45:47 IST,2018-06-04,18:45:47,+0530,44438256,matthewherper,Matthew Herper,,And the winner of #ASCO18 is metformin! And caution! $BLUE $LOXO $MRK $NKTR $GHDX  https://t.co/9MNU6uiY25,en,[],['https://www.forbes.com/sites/matthewherper/2018/06/04/winners-and-losers-from-cancer-researchs-biggest-event/#16ffd6c461bf'],[],3,17,42,['asco18'],"['blue', 'loxo', 'mrk', 'nktr', 'ghdx']",https://twitter.com/matthewherper/status/1003626367420858368,False,,0,,,,,,,,[],,,,
1003599839970684928,1003599839970684928,2018-06-04 17:00:22 IST,2018-06-04,17:00:22,+0530,47678782,megtirrell,Meg Tirrell,,Catching up on #ASCO18 out of the weekend? Here's what you need to know:  https://t.co/z0NUvEoVoe $MRK $BMY $RHHBY $LOXO $BPMC $NKTR $GHDX,en,[],['https://www.cnbc.com/2018/06/04/asco-the-worlds-largest-cancer-research-conference-5-takeaways.html'],[],1,11,25,['asco18'],"['mrk', 'bmy', 'rhhby', 'loxo', 'bpmc', 'nktr', 'ghdx']",https://twitter.com/megtirrell/status/1003599839970684928,False,,0,,,,,,,,[],,,,
1003574911259041792,1003574911259041792,2018-06-04 15:21:19 IST,2018-06-04,15:21:19,+0530,47678782,megtirrell,Meg Tirrell,,"Early #ASCO18 movers: $BLUE -5.9% $BPMC -3.6% $MRK +1.2% $BMY -0.4% $NKTR -17% Light volume, $LOXO not yet showing pre-market trades. Stay tuned to @CNBC for more",en,"[{'screen_name': 'cnbc', 'name': 'cnbc', 'id': '20402945'}]",[],[],6,19,51,['asco18'],"['blue', 'bpmc', 'mrk', 'bmy', 'nktr', 'loxo']",https://twitter.com/megtirrell/status/1003574911259041792,False,,0,,,,,,,,[],,,,
1003405913666007040,1003405913666007040,2018-06-04 04:09:46 IST,2018-06-04,04:09:46,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"$NKTR - JPM cut price target to $78 from $90 to reflect ‚Äúmore conservative‚Äù stance for ‚Äò214 in lung. Oh, remember lung cancer? That was MIA from yesterday‚Äôs presentation.",en,[],[],[],3,5,8,[],['nktr'],https://twitter.com/adamfeuerstein/status/1003405913666007040,False,,0,,,,,,,,[],,,,
1003386695453151232,1003385554359214080,2018-06-04 02:53:24 IST,2018-06-04,02:53:24,+0530,102094857,adamfeuerstein,Adam Feuerstein,,@bradloncar $NKTR was Twitter‚Äôs fault? That‚Äôs an interesting observation.,en,[],[],[],3,1,10,[],['nktr'],https://twitter.com/adamfeuerstein/status/1003386695453151232,False,,0,,,,,,,,"[{'screen_name': 'bradloncar', 'name': 'Brad Loncar', 'id': '274233761'}]",,,,
1003380929333776384,1003380929333776384,2018-06-04 02:30:30 IST,2018-06-04,02:30:30,+0530,102754598,johncendpts,John Carroll,,"Nektar wants everyone to stay calm as they carry on with NKTR-214, hoping to avoid an #ASCO18 stampede $NKTR $BMY   https://t.co/WEGqDXI0gx",en,[],['https://endpts.com/nektar-wants-everyone-to-stay-calm-as-they-carry-on-with-nktr-214-hoping-to-avoid-an-asco-stampede/'],[],2,14,19,['asco18'],"['nktr', 'bmy']",https://twitter.com/JohnCendpts/status/1003380929333776384,False,,0,,,,,,,,[],,,,
1003254550134915074,1003254550134915074,2018-06-03 18:08:18 IST,2018-06-03,18:08:18,+0530,102094857,adamfeuerstein,Adam Feuerstein,,A controversial #ASCO18 presentation underscores risk $BMY $NKTR carry with experimental cancer drug  https://t.co/QKzGshqbtB,en,[],['https://www.statnews.com/2018/06/03/asco-bristol-nektar-combination/'],[],4,15,35,['asco18'],"['bmy', 'nktr']",https://twitter.com/adamfeuerstein/status/1003254550134915074,False,,0,,,,,,,,[],,,,
1003073529812865025,1003073529812865025,2018-06-03 06:09:00 IST,2018-06-03,06:09:00,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Dear $NKTR &amp; $BMY ‚Äî  Maybe you should have run a simple and reliable randomized, controlled clinical trial?  Sincerely,  Science.   #ASCO18",en,[],[],[],5,10,75,['asco18'],"['nktr', 'bmy']",https://twitter.com/adamfeuerstein/status/1003073529812865025,False,,0,,,,,,,,[],,,,
1003062193699606528,1003062193699606528,2018-06-03 05:23:57 IST,2018-06-03,05:23:57,+0530,44438256,matthewherper,Matthew Herper,,Nektar And Bristol Hurtle Forward With Experimental Cancer Drug $NKTR $BMY #ASCO18  https://t.co/AX5rv4PW20,en,[],['https://www.forbes.com/sites/matthewherper/2018/06/02/nektar-and-bristol-hurtle-forward-with-experimental-cancer-drug/#94b98dc45b6d'],[],2,10,19,['asco18'],"['nktr', 'bmy']",https://twitter.com/matthewherper/status/1003062193699606528,False,,0,,,,,,,,[],,,,
1003054277907177472,1003054277907177472,2018-06-03 04:52:30 IST,2018-06-03,04:52:30,+0530,44438256,matthewherper,Matthew Herper,,"OK. I understand the $NKTR data now. Spoke to the company. Stage 2 started before responses to Stage 1 had fully accumulated; therefore they make based on study criteria in all cases. (Seemed like it should be true, but didn't make sense.)",en,[],[],[],0,7,8,[],['nktr'],https://twitter.com/matthewherper/status/1003054277907177472,False,,0,,,,,,,,[],,,,
1003039136062767104,1003039136062767104,2018-06-03 03:52:20 IST,2018-06-03,03:52:20,+0530,6810242,bydavidcrow,David Crow,,By far most important takeaway from Nektar data is apparent ability to generate reaponse in PDL1 negative patients. #ASCO18 $NKTR  https://t.co/AHeWSfkaYf,en,[],[],['https://pbs.twimg.com/media/DeuCxnvW0AAxXjX.jpg'],2,3,12,['asco18'],['nktr'],https://twitter.com/bydavidcrow/status/1003039136062767104,False,,1,https://pbs.twimg.com/media/DeuCxnvW0AAxXjX.jpg,,,,,,,[],,,,
997141777273507840,997141777273507840,2018-05-17 21:18:20 IST,2018-05-17,21:18:20,+0530,873399943,jacobplieth,Jacob Plieth,,"Early #ASCO18 combo winners and losers, via @EPVantage  https://t.co/qoLEdIi8W3 $LLY $ARMO $JNCE $NKTR",en,"[{'screen_name': 'epvantage', 'name': 'vantage', 'id': '841963175729856512'}]",['http://bit.ly/2KAa8LN'],[],2,13,11,['asco18'],"['lly', 'armo', 'jnce', 'nktr']",https://twitter.com/JacobPlieth/status/997141777273507840,False,,0,,,,,,,,[],,,,
996858462612131841,996858462612131841,2018-05-17 02:32:32 IST,2018-05-17,02:32:32,+0530,102094857,adamfeuerstein,Adam Feuerstein,,Combination cancer immunotherapies take center stage at ASCO‚Äôs annual meeting  https://t.co/jRcxRthqV5 #ASCO18 $NKTR $DVAX $JNCE $SNDX $IDRA,en,[],['https://www.statnews.com/2018/05/16/asco-combination-cancer-immunotherapies/'],[],4,17,20,['asco18'],"['nktr', 'dvax', 'jnce', 'sndx', 'idra']",https://twitter.com/adamfeuerstein/status/996858462612131841,False,,0,,,,,,,,[],,,,
996858075167502339,996858075167502339,2018-05-17 02:31:00 IST,2018-05-17,02:31:00,+0530,873399943,jacobplieth,Jacob Plieth,,$NKTR $BMY ORR in ITT 53% (vs 50% at SITC); ORR in PD-L1 negatives 52% (vs 43% at SITC) #ASCO18 Opinions?  https://t.co/jfpxJPR84u,in,[],[],['https://pbs.twimg.com/media/DdVGFx9WsAEIWCh.jpg'],6,6,16,['asco18'],"['nktr', 'bmy']",https://twitter.com/JacobPlieth/status/996858075167502339,False,,1,https://pbs.twimg.com/media/DdVGFx9WsAEIWCh.jpg,,,,,,,[],,,,
984039969558876160,984039969558876160,2018-04-11 17:36:25 IST,2018-04-11,17:36:25,+0530,102094857,adamfeuerstein,Adam Feuerstein,,And the $NKTR bulls say: Who needs a checkpoint inhibitor?  https://t.co/FxDxHmTek6,en,[],['https://twitter.com/odibro/status/984039492087631873'],[],2,0,6,[],['nktr'],https://twitter.com/adamfeuerstein/status/984039969558876160,False,https://twitter.com/odibro/status/984039492087631873,0,,,,,,,,[],,,,
982241342959923202,982241342959923202,2018-04-06 18:29:19 IST,2018-04-06,18:29:19,+0530,102094857,adamfeuerstein,Adam Feuerstein,,$NKTR is the new $INCY. Anyone worried about that now?,en,[],[],[],10,5,19,[],"['nktr', 'incy']",https://twitter.com/adamfeuerstein/status/982241342959923202,False,,0,,,,,,,,[],,,,
978611761543831552,978611761543831552,2018-03-27 18:06:40 IST,2018-03-27,18:06:40,+0530,873399943,jacobplieth,Jacob Plieth,,"Cytokines, the immuno-oncology stars of 2018. New report from @EPVantage $NKTR $ALKS $ARMO  https://t.co/vvZ4Qc2jfM",en,"[{'screen_name': 'epvantage', 'name': 'vantage', 'id': '841963175729856512'}]",['http://info.evaluategroup.com/rs/607-YGS-364/images/2018-03-cytokines.pdf'],[],4,27,47,[],"['nktr', 'alks', 'armo']",https://twitter.com/JacobPlieth/status/978611761543831552,False,,0,,,,,,,,[],,,,
971040497354661889,971040497354661889,2018-03-06 20:41:10 IST,2018-03-06,20:41:10,+0530,873399943,jacobplieth,Jacob Plieth,,I recently put together two reviews of cytokine therapies via @EPVantage: IL-2/IL-15  https://t.co/ORcoWd8pKl. IL-10/IL-12  https://t.co/UcIY22eLlV $NKTR $ALKS $ARMO,en,"[{'screen_name': 'epvantage', 'name': 'vantage', 'id': '841963175729856512'}]","['http://epvantage.com/Universal/View.aspx?type=Story&id=767964&isEPVantage=yes', 'http://epvantage.com/Universal/View.aspx?type=Story&id=769600&isEPVantage=yes']",[],2,22,44,[],"['nktr', 'alks', 'armo']",https://twitter.com/JacobPlieth/status/971040497354661889,False,,0,,,,,,,,[],,,,
969336084177006593,969336084177006593,2018-03-02 03:48:26 IST,2018-03-02,03:48:26,+0530,274233761,bradloncar,Brad Loncar,,$NKTR says their RCC ORR has increased from 57% at #JPM18 to 71% now.,en,[],[],[],5,13,49,['jpm18'],['nktr'],https://twitter.com/bradloncar/status/969336084177006593,False,,0,,,,,,,,[],,,,
967839866317713408,967839866317713408,2018-02-26 00:43:00 IST,2018-02-26,00:43:00,+0530,274233761,bradloncar,Brad Loncar,,This week's earnings calendar:  M: $CLVS $EXEL T: $ACAD $FGEN $TSRO W: $HZNP $MYL $VRX T: $NKTR $PBYI $SRPT  Full schedule:  https://t.co/Ecf1Po8wvT  https://t.co/O2qRMw1TI8,en,[],['http://www.loncarblog.com/february-26-earnings'],['https://pbs.twimg.com/media/DW1LOyZUMAASYcl.jpg'],3,14,43,[],"['clvs', 'exel', 'acad', 'fgen', 'tsro', 'hznp', 'myl', 'vrx', 'nktr', 'pbyi', 'srpt']",https://twitter.com/bradloncar/status/967839866317713408,False,,1,https://pbs.twimg.com/media/DW1LOyZUMAASYcl.jpg,,,,,,,[],,,,
963754575802007552,963754575802007552,2018-02-14 18:09:31 IST,2018-02-14,18:09:31,+0530,873399943,jacobplieth,Jacob Plieth,,Here's the NKTR-214 data that started it all $NKTR  https://t.co/XLdKTzoyOA $BMY,en,[],['http://epvantage.com/Universal/View.aspx?type=Story&id=746916&isEPVantage=yes'],[],0,11,14,[],"['nktr', 'bmy']",https://twitter.com/JacobPlieth/status/963754575802007552,False,,0,,,,,,,,[],,,,
963752869689221121,963752869689221121,2018-02-14 18:02:44 IST,2018-02-14,18:02:44,+0530,102754598,johncendpts,John Carroll,,"To me, the big takeaway from the $NKTR deal is you either have a leading combo now or you risk near-term commoditization of your PD-1/L1. $BMY $MRK $AZN",en,[],[],[],0,7,18,[],"['nktr', 'bmy', 'mrk', 'azn']",https://twitter.com/JohnCendpts/status/963752869689221121,False,,0,,,,,,,,[],,,,
963752131286233088,963752131286233088,2018-02-14 17:59:48 IST,2018-02-14,17:59:48,+0530,274233761,bradloncar,Brad Loncar,,This is the data that $NKTR has presented so far. What Bristol is paying so much for is all those red bars that signify PD-1 negative patients.  https://t.co/Aug5ie4CAK,en,[],[],['https://pbs.twimg.com/media/DV_va7KUMAEik5M.jpg'],5,29,51,[],['nktr'],https://twitter.com/bradloncar/status/963752131286233088,False,,1,https://pbs.twimg.com/media/DV_va7KUMAEik5M.jpg,,,,,,,[],,,,
963746987593125889,963746987593125889,2018-02-14 17:39:22 IST,2018-02-14,17:39:22,+0530,44438256,matthewherper,Matthew Herper,,$BMY To Pay Largest Licensing Fee In Biotech History For $NKTR  Cancer Drug  https://t.co/PcJywhsSMn,en,[],['https://www.forbes.com/sites/matthewherper/2018/02/14/bristol-myers-to-pay-largest-licensing-fee-in-biotech-history-for-cancer-drug/#16c7e3ce6d29'],[],2,27,34,[],"['bmy', 'nktr']",https://twitter.com/matthewherper/status/963746987593125889,False,,0,,,,,,,,[],,,,
963746540253794304,963746540253794304,2018-02-14 17:37:35 IST,2018-02-14,17:37:35,+0530,274233761,bradloncar,Brad Loncar,,$1.85 billion upfront. Wow. $NKTR $BMY,en,[],[],[],2,4,17,[],"['nktr', 'bmy']",https://twitter.com/bradloncar/status/963746540253794304,False,,0,,,,,,,,[],,,,
963745756443217921,963745756443217921,2018-02-14 17:34:28 IST,2018-02-14,17:34:28,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"The over/under on the first $NKTR ""no takeout‚Äù tweet was 3 seconds. The under wins.",en,[],[],[],3,1,15,[],['nktr'],https://twitter.com/adamfeuerstein/status/963745756443217921,False,,0,,,,,,,,[],,,,
963745591418347520,963745591418347520,2018-02-14 17:33:49 IST,2018-02-14,17:33:49,+0530,102754598,johncendpts,John Carroll,,"The deal terms on this $BMY / $NKTR deal are extraordinary. Record upfront for a minority share in '214. Nektar retains full pricing power, BMY to cover most R&amp;D costs -- just huge  https://t.co/qwE4plaeb0",en,[],['https://endpts.com/bristol-myers-lassos-the-next-big-thing-in-i-o-grabs-214-rights-in-a-record-3-6b-deal-with-nektar/'],[],1,31,30,[],"['bmy', 'nktr']",https://twitter.com/JohnCendpts/status/963745591418347520,False,,0,,,,,,,,[],,,,
963744868928540673,963744868928540673,2018-02-14 17:30:56 IST,2018-02-14,17:30:56,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"$BMY, needing a cancer immunotherapy boost, pays shockingly steep price for $NKTR drug  https://t.co/RvjHAvw6uf Wowza, these deal terms for NKTR-214 are $$$$$$$",en,[],['https://www.statnews.com/2018/02/14/bristol-cancer-immunotherapy-nektar/'],[],4,11,18,[],"['bmy', 'nktr']",https://twitter.com/adamfeuerstein/status/963744868928540673,False,,0,,,,,,,,[],,,,
963744448856379394,963744448856379394,2018-02-14 17:29:16 IST,2018-02-14,17:29:16,+0530,102754598,johncendpts,John Carroll,,"Bristol-Myers lassos the next big thing in I/O, grabs ‚Äò214 rights in a record $3.6B deal with Nektar $BMY $NKTR  https://t.co/qwE4plaeb0",en,[],['https://endpts.com/bristol-myers-lassos-the-next-big-thing-in-i-o-grabs-214-rights-in-a-record-3-6b-deal-with-nektar/'],[],0,13,17,[],"['bmy', 'nktr']",https://twitter.com/JohnCendpts/status/963744448856379394,False,,0,,,,,,,,[],,,,
959527156454916097,959527156454916097,2018-02-03 02:11:15 IST,2018-02-03,02:11:15,+0530,102754598,johncendpts,John Carroll,,Buyout buzz hits fever pitch on report that Nektar is ‚Äòexploring options‚Äô $NKTR  https://t.co/fd3b8I3iVX,en,[],['https://endpts.com/buyout-buzz-hits-fever-pitch-on-report-that-nektar-is-exploring-options/'],[],1,9,8,[],['nktr'],https://twitter.com/JohnCendpts/status/959527156454916097,False,,0,,,,,,,,[],,,,
953226013965803520,953226013965803520,2018-01-16 16:52:46 IST,2018-01-16,16:52:46,+0530,701464597,cowenresearch,cowenresearch,,"Our #biotech team reviews key themes for 2018 and previews 4Q earnings, including $AGIO $ARRY $BIVV $ESPR $FOLD $HRTX $GWPH $IMMU $IRWD $NBIX $NKTR $ONCE $RARE $SRPT $ALXN $VRTX",en,[],[],[],0,1,8,['biotech'],"['agio', 'arry', 'bivv', 'espr', 'fold', 'hrtx', 'gwph', 'immu', 'irwd', 'nbix', 'nktr', 'once', 'rare', 'srpt', 'alxn', 'vrtx']",https://twitter.com/CowenResearch/status/953226013965803520,False,,0,,,,,,,,[],,,,
951923960635109378,951923960635109378,2018-01-13 02:38:52 IST,2018-01-13,02:38:52,+0530,274233761,bradloncar,Brad Loncar,,"Listening to the $NKTR #JPM18 presentation. Great quote about their melanoma data...""This isn't even a spider plot, it's a limp squid.""  https://t.co/ocA23GNaRW",en,[],[],['https://pbs.twimg.com/media/DTXpxtsVAAA-tUc.jpg'],1,8,26,['jpm18'],['nktr'],https://twitter.com/bradloncar/status/951923960635109378,False,,1,https://pbs.twimg.com/media/DTXpxtsVAAA-tUc.jpg,,,,,,,[],,,,
951856722439786497,951856722439786497,2018-01-12 22:11:41 IST,2018-01-12,22:11:41,+0530,274233761,bradloncar,Brad Loncar,,$NKTR is up more than $7 billion since #SITC17.,en,[],[],[],4,1,6,['sitc17'],['nktr'],https://twitter.com/bradloncar/status/951856722439786497,False,,0,,,,,,,,[],,,,
951797380982165504,951797380982165504,2018-01-12 18:15:53 IST,2018-01-12,18:15:53,+0530,102094857,adamfeuerstein,Adam Feuerstein,,We went to #JPM18 with burning questions about biotechs. We got some answers  https://t.co/BTKyZk14d3 My final üî• takes on $INCY $CELG $NKTR ...,en,[],['https://www.statnews.com/2018/01/12/burning-answers-jpm18/'],[],0,4,13,['jpm18'],"['incy', 'celg', 'nktr']",https://twitter.com/adamfeuerstein/status/951797380982165504,False,,0,,,,,,,,[],,,,
950877934675480576,950877934675480576,2018-01-10 05:22:20 IST,2018-01-10,05:22:20,+0530,19400611,cvpayne,Charles V Payne,,Nektar Therapeutics $NKTR shares up from $11 to $69 might be something to this- I hope the crisis is heartbreaking  https://t.co/4697CbnWTh,en,[],['https://twitter.com/sav01/status/950876613125615616'],[],2,5,21,[],['nktr'],https://twitter.com/cvpayne/status/950877934675480576,False,https://twitter.com/sav01/status/950876613125615616,0,,,,,,,,[],,,,
950864601880576000,950864601880576000,2018-01-10 04:29:21 IST,2018-01-10,04:29:21,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"We woke up early and stayed out late: Here‚Äôs what you need to know from #JPM18 Day Two  https://t.co/qy9dbHfu2l $BMY M&amp;A insight, $BLUE $NKTR $INCY $AXON",en,[],['https://www.statnews.com/2018/01/09/jpm18-bluebird-axovant-nektar/'],[],0,8,24,['jpm18'],"['bmy', 'blue', 'nktr', 'incy', 'axon']",https://twitter.com/adamfeuerstein/status/950864601880576000,False,,0,,,,,,,,[],,,,
950826068268724226,950826068268724226,2018-01-10 01:56:14 IST,2018-01-10,01:56:14,+0530,102094857,adamfeuerstein,Adam Feuerstein,,Easier (less risky) to pour money into $NKTR -214 with tiny amount of data and no pivotal catalyst in sight than $INCY and its make-or-break IDO ph3 readout looming. #JPM18,en,[],[],[],5,1,14,['jpm18'],"['nktr', 'incy']",https://twitter.com/adamfeuerstein/status/950826068268724226,False,,0,,,,,,,,[],,,,
945383820974575618,945383820974575618,2017-12-26 01:30:41 IST,2017-12-26,01:30:41,+0530,15568127,themotleyfool,The Motley Fool,,"If your New Year‚Äôs wish is for cancer treatment breakthroughs, Incyte, Nektar Therapeutics, and Bristol-Myers Squibb hope to deliver. $INCY $NKTR $BMY  https://t.co/19pUW59uxo",en,[],['https://www.fool.com/investing/2017/12/22/if-i-could-only-buy-1-healthcare-stock-in-january.aspx'],[],0,9,22,[],"['incy', 'nktr', 'bmy']",https://twitter.com/themotleyfool/status/945383820974575618,False,,0,,,,,,,,[],,,,
943467346861133824,943467346861133824,2017-12-20 18:35:18 IST,2017-12-20,18:35:18,+0530,274233761,bradloncar,Brad Loncar,,$PIRS $NKTR $IDRA added to the cancer immunotherapy index.  https://t.co/pYdPHtJyII  https://t.co/sYG6zIAHON,en,[],['http://www.loncarindex.com/december-2017-rebalance'],['https://pbs.twimg.com/media/DRfehPdUQAAPLDn.jpg'],4,19,54,[],"['pirs', 'nktr', 'idra']",https://twitter.com/bradloncar/status/943467346861133824,False,,1,https://pbs.twimg.com/media/DRfehPdUQAAPLDn.jpg,,,,,,,[],,,,
930052453998919681,930052453998919681,2017-11-13 18:09:19 IST,2017-11-13,18:09:19,+0530,102754598,johncendpts,John Carroll,,Nektar takes the spotlight at SITC touting some promising early data for hard-to-treat cancers $NKTR +23% #SITC2017  https://t.co/gc7wx25Hwf,en,[],['https://endpts.com/nektar-takes-the-spotlight-at-sitc-touting-some-promising-early-data-for-hard-to-treat-cancers/'],[],0,13,15,['sitc2017'],['nktr'],https://twitter.com/JohnCendpts/status/930052453998919681,False,,0,,,,,,,,[],,,,
889449200202723328,889448465822081024,2017-07-24 17:06:29 IST,2017-07-24,17:06:29,+0530,873399943,jacobplieth,Jacob Plieth,,"Here's the $150m up-front $LLY paid $NKTR relative to other deals at phase I or earlier, via @evaluatepharma  https://t.co/PvdqjMMjNt",en,"[{'screen_name': 'evaluatepharma', 'name': 'evaluate pharma', 'id': '43901066'}]",[],['https://pbs.twimg.com/media/DFf1NAyXcAAef5K.jpg'],0,11,24,[],"['lly', 'nktr']",https://twitter.com/JacobPlieth/status/889449200202723328,False,,1,https://pbs.twimg.com/media/DFf1NAyXcAAef5K.jpg,,,,,,,[],,,,
889448465822081024,889448465822081024,2017-07-24 17:03:34 IST,2017-07-24,17:03:34,+0530,873399943,jacobplieth,Jacob Plieth,,"Interesting, though early-stage, $NKTR asset picked up by $LLY. Preclinical data (&amp; Treg mech) presented at #WCI2017 on NKTR-358 this month  https://t.co/68QTihdy9X",en,[],[],['https://pbs.twimg.com/media/DFf0hooXgAIA9x2.jpg'],7,10,11,['wci2017'],"['nktr', 'lly']",https://twitter.com/JacobPlieth/status/889448465822081024,False,,1,https://pbs.twimg.com/media/DFf0hooXgAIA9x2.jpg,,,,,,,[],,,,
889447792040714240,889447792040714240,2017-07-24 17:00:53 IST,2017-07-24,17:00:53,+0530,102754598,johncendpts,John Carroll,,Eli Lilly offers $400M-plus deal to bag an early-stage autoimmune drug from Nektar $LLY $NKTR  https://t.co/xJv813JJGK,en,[],['https://endpts.com/eli-lilly-buys-into-a-400m-plus-deal-for-an-early-stage-autoimmune-drug-from-nektar/'],[],2,19,15,[],"['lly', 'nktr']",https://twitter.com/JohnCendpts/status/889447792040714240,False,,0,,,,,,,,[],,,,
889447698742562816,889447698742562816,2017-07-24 17:00:31 IST,2017-07-24,17:00:31,+0530,102094857,adamfeuerstein,Adam Feuerstein,,$NKTR licensed ph1 immunology drug to $LLY. $150M upfront.,en,[],[],[],0,9,8,[],"['nktr', 'lly']",https://twitter.com/adamfeuerstein/status/889447698742562816,False,,0,,,,,,,,[],,,,
887281643790139400,887281643790139400,2017-07-18 17:33:23 IST,2017-07-18,17:33:23,+0530,102094857,adamfeuerstein,Adam Feuerstein,,$NKTR reports progress in making an opioid pain pill that addicts don‚Äôt much like ‚Äî&gt;  https://t.co/d9IrZsAwf0,en,[],['https://www.statnews.com/2017/07/18/nektar-therapeutics-opioid/'],[],2,9,13,[],['nktr'],https://twitter.com/adamfeuerstein/status/887281643790139400,False,,0,,,,,,,,[],,,,
887280924542500864,887280924542500864,2017-07-18 17:30:31 IST,2017-07-18,17:30:31,+0530,102754598,johncendpts,John Carroll,,Back from the dead: Nektar hunts a blockbuster deal as opioid ‚Äò181 looks less addictive than oxy $NKTR  https://t.co/EJG6W7Wfkp,en,[],['https://endpts.com/back-from-the-dead-nektar-hunts-a-blockbuster-deal-as-opioid-181-looks-less-addictive-than-oxy/'],[],3,8,10,[],['nktr'],https://twitter.com/JohnCendpts/status/887280924542500864,False,,0,,,,,,,,[],,,,
843832391080775680,843832391080775680,2017-03-20 20:01:34 IST,2017-03-20,20:01:34,+0530,47678782,megtirrell,Meg Tirrell,,Big day for biotech movers: $CYTM +24% on $BMY deal $NKTR +32% on phase 3 data $ESPR +54% on FDA guidance,en,[],[],[],0,9,15,[],"['cytm', 'bmy', 'nktr', 'espr']",https://twitter.com/megtirrell/status/843832391080775680,False,,0,,,,,,,,[],,,,
843786927065251840,843786927065251840,2017-03-20 17:00:54 IST,2017-03-20,17:00:54,+0530,102094857,adamfeuerstein,Adam Feuerstein,,$NKTR Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study ‚Äî&gt;  https://t.co/k3U4ELB5mZ w/ cautious comment from @DavidJuurlink,en,"[{'screen_name': 'davidjuurlink', 'name': 'david juurlink', 'id': '473179284'}]",['https://www.thestreet.com/story/14050428/1/nektar-addiction-resistant-opioid-reduces-chronic-pain-in-late-stage-study.html'],[],3,17,24,[],['nktr'],https://twitter.com/adamfeuerstein/status/843786927065251840,False,,0,,,,,,,,[],,,,
780724011156250624,780724011156250624,2016-09-27 16:31:24 IST,2016-09-27,16:31:24,+0530,274233761,bradloncar,Brad Loncar,,$BMY and $NKTR will do combos of Opdivo and NKTR-214 (CD122).  https://t.co/ghy9JMb8CA,nl,[],['http://investor.bms.com/investors/news-and-events/press-releases/press-release-details/2016/Bristol-Myers-Squibb-and-Nektar-Therapeutics-Announce-Oncology-Clinical-Collaboration-to-Evaluate-the-Combination-of-Opdivo-nivolumab-and-NKTR-214/default.aspx'],[],1,3,5,[],"['bmy', 'nktr']",https://twitter.com/bradloncar/status/780724011156250624,False,,0,,,,,,,,[],,,,
715538734427611136,715538734427611136,2016-03-31 19:28:23 IST,2016-03-31,19:28:23,+0530,274233761,bradloncar,Brad Loncar,,"Emerging players in the immunotherapy space. From left to right, reps from $AGEN $FPRX $NKTR $ADRO and $DVAX.  https://t.co/wAW7pmPeKn",en,[],[],['https://pbs.twimg.com/media/Ce4ara2XEAEA7UR.jpg'],1,2,7,[],"['agen', 'fprx', 'nktr', 'adro', 'dvax']",https://twitter.com/bradloncar/status/715538734427611136,False,,1,https://pbs.twimg.com/media/Ce4ara2XEAEA7UR.jpg,,,,,,,[],,,,
697836060194246656,697836060194246656,2016-02-11 23:04:16 IST,2016-02-11,23:04:16,+0530,19988458,dougkass,Dougie Kass,,"@jimcramer  RM: Purchased basket of 12 biotech stocks this morning: $ACAD $AERI $CELG $CEMP, $GILD $NKTR $NVAX $OTIC $PTLA $SAGE $TTPH $XON",en,[],[],[],9,8,18,[],"['acad', 'aeri', 'celg', 'cemp', 'gild', 'nktr', 'nvax', 'otic', 'ptla', 'sage', 'ttph', 'xon']",https://twitter.com/DougKass/status/697836060194246656,False,,0,,,,,,,,[],,,,
684409875443625984,684409875443625984,2016-01-05 21:53:24 IST,2016-01-05,21:53:24,+0530,47678782,megtirrell,Meg Tirrell,,"And more drug price increase news, per Jefferies $AGN $NKTR $AZN $PRGO $BIIB $SHPG $XNPT  https://t.co/vQCeklHydD",en,[],[],['https://pbs.twimg.com/media/CX-DJt_W8AAUOe3.jpg'],2,12,9,[],"['agn', 'nktr', 'azn', 'prgo', 'biib', 'shpg', 'xnpt']",https://twitter.com/megtirrell/status/684409875443625984,False,,1,https://pbs.twimg.com/media/CX-DJt_W8AAUOe3.jpg,,,,,,,[],,,,
681949168743485440,681949168743485440,2015-12-30 02:55:26 IST,2015-12-30,02:55:26,+0530,274233761,bradloncar,Brad Loncar,,Biotech stocks closing the year near 52 week highs: $ALKS $NBIX $QGEN $CBPO $OPHT $NKTR $LGND $XLRN $GHDX $DERM.,en,[],[],[],4,13,20,[],"['alks', 'nbix', 'qgen', 'cbpo', 'opht', 'nktr', 'lgnd', 'xlrn', 'ghdx', 'derm']",https://twitter.com/bradloncar/status/681949168743485440,False,,0,,,,,,,,[],,,,
